Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 9c; Approves $75M Stock Buyback Plan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Eagle Pharmaceuticals, Inc. Reports Second Quarter 2016 Results
August 9, 2016 6:50 AM EDT
-- Bendeka market share grows to 80% --
-- Positive FDA
meeting on Ryanodex for EHS --
-- Eagle purchases Ryanodex
royalty --
-- Announces $75 million share repurchase
program --
-- Q2 EPS increases to $0.84 per basic and $0.80
per diluted, Total Revenue $40.9 million --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Eagle or the Company) (Nasdaq: EGRX) today announced its financial results for the three- and six-months ended June 30, 2016. Highlights of and subsequent to the second quarter of 2016 include:
Business Highlights:... More
Eagle Pharmaceuticals Reports Positive Outcome From FDA Meeting For RYANODEX For Exertional Heat Stroke NDA Submission
August 9, 2016 6:45 AM EDT-- Hajj Study Results Sufficient for Human Data in Filing --
-- Hybrid Rule (Human and Animal Data) Reaffirmed --
-- Only Completion of Ongoing Animal Studies Required for Submission--
-- Eagle Purchases Royalty Rights to Ryanodex Portfolio --
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals (Eagle or the Company) (NASDAQ: EGRX) today announced that the U.S. Food and Drug Administration ("FDA") has determined that no additional human safety and efficacy data is required for the... More
